Vaccination of Melanoma Patients Using Dendritic Cells Loaded with an Allogeneic Tumor Cell Lysate

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2005 Sep 28

PMID 16187085

Citations 49

Authors

Margarita Salcedo

Nadege Bercovici

Rachel Taylor

Pierre Vereecken

Severine Massicard

Dominique Duriau

Frederique Vernel-Pauillac

Aurelie Boyer

Veronique Baron-Bodo

Eric Mallard

Jacques Bartholeyns

Beatrice Goxe

Nathalie Latour

Sophie Leroy

Didier Prigent

Philippe Martiat

Francois Sales

Marianne Laporte

Catherine Bruyns

Jean-Loup Romet-Lemonne

Jean-Pierre Abastado

Frederic Lehmann

Thierry Velu

Affiliations

Soon will be listed here.

Abstract

The aim of the present phase I/II study was to evaluate the safety, immune responses and clinical activity of a vaccine based on autologous dendritic cells (DC) loaded with an allogeneic tumor cell lysate in advanced melanoma patients. DC derived from monocytes were generated in serum-free medium containing GM-CSF and IL-13 according to Good Manufacturing Practices. Fifteen patients with metastatic melanoma (stage III or IV) received four subcutaneous, intradermal, and intranodal vaccinations of both DC loaded with tumor cell lysate and DC loaded with hepatitis B surface protein (HBs) and/or tetanus toxoid (TT). No grade 3 or 4 adverse events related to the vaccination were observed. Enhanced immunity to the allogeneic tumor cell lysate and to TAA-derived peptides were documented, as well as immune responses to HBs/TT antigens. Four out of nine patients who received the full treatment survived for more than 20 months. Two patients showed signs of clinical response and received 3 additional doses of vaccine: one patient showed regression of in-transit metastases leading to complete remission. Eighteen months later, the patient was still free of disease. The second patient experienced stabilization of lung metastases for approximately 10 months. Overall, our results show that vaccination with DC loaded with an allogeneic melanoma cell lysate was feasible in large-scale and well-tolerated in this group of advanced melanoma patients. Immune responses to tumor-related antigens documented in some treated patients support further investigations to optimize the vaccine formulation.

Citing Articles

Boosting immunotherapy efficacy: Empowering the Potency of Dendritic cells loaded with breast cancer lysates through CTLA-4 suppression.

Bakhshivand M, Masoumi J, Ghorbaninezhad F, Aghebati-Maleki L, Shanebandi D, Sandoghchian Shotorbani S Heliyon. 2024; 10(18):e37699.

PMID: 39309891 PMC: 11416247. DOI: 10.1016/j.heliyon.2024.e37699.

Current Trends and Innovative Approaches in Cancer Immunotherapy.

Kim J, Maharjan R, Park J AAPS PharmSciTech. 2024; 25(6):168.

PMID: 39044047 PMC: 11573471. DOI: 10.1208/s12249-024-02883-x.

Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles.

Sweeney E, Sekhri P, Telaraja D, Chen J, Chin S, Chiappinelli K Cytotherapy. 2023; 25(7):718-727.

PMID: 37278683 PMC: 10264146. DOI: 10.1016/j.jcyt.2023.03.014.

Recent Advances in Experimental Dendritic Cell Vaccines for Cancer.

Filin I, Kitaeva K, Rutland C, Rizvanov A, Solovyeva V Front Oncol. 2021; 11:730824.

PMID: 34631558 PMC: 8495208. DOI: 10.3389/fonc.2021.730824.

Current Trends in Cancer Immunotherapy.

Filin I, Solovyeva V, Kitaeva K, Rutland C, Rizvanov A Biomedicines. 2020; 8(12).

PMID: 33348704 PMC: 7766207. DOI: 10.3390/biomedicines8120621.

References

Brossart P, Bevan M . Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood. 1997; 90(4):1594-9. PMC: 2778580. View

Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A . Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer. 2003; 89(8):1463-72. PMC: 2394334. DOI: 10.1038/sj.bjc.6601243. View

CHAKRABORTY N, Sporn J, Tortora A, Kurtzman S, Yamase H, ERGIN M . Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother. 1998; 47(1):58-64. PMC: 11037302. DOI: 10.1007/s002620050504. View

de Vries I, Lesterhuis W, Scharenborg N, Engelen L, Ruiter D, Gerritsen M . Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003; 9(14):5091-100. View

Banchereau J, Palucka A, Dhodapkar M, Burkeholder S, Taquet N, Rolland A . Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61(17):6451-8. View

Mitchell M, Kan-Mitchell J, Morrow P, Darrah D, Jones V, Mescher M . Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res. 2004; 10(1 Pt 1):76-83. DOI: 10.1158/1078-0432.ccr-0689-3. View

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

Boccaccio C, Jacod S, Kaiser A, Boyer A, Abastado J, Nardin A . Identification of a clinical-grade maturation factor for dendritic cells. J Immunother. 2002; 25(1):88-96. DOI: 10.1097/00002371-200201000-00010. View

Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B . Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003; 63(19):6478-87. View

10.

Griffioen M, Borghi M, Schrier P, Osanto S, Schadendorf D . Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol Immunother. 2004; 53(8):715-22. PMC: 11036789. DOI: 10.1007/s00262-004-0514-z. View

11.

Marie Svane I, Soot M, Buus S, Johnsen H . Clinical application of dendritic cells in cancer vaccination therapy. APMIS. 2003; 111(7-8):818-34. DOI: 10.1034/j.1600-0463.2003.11107813.x. View

12.

Berard F, Blanco P, Davoust J, Neidhart-Berard E, Nouri-Shirazi M, Taquet N . Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000; 192(11):1535-44. PMC: 2193101. DOI: 10.1084/jem.192.11.1535. View

13.

Yu J, Liu G, Ying H, Yong W, Black K, Wheeler C . Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004; 64(14):4973-9. DOI: 10.1158/0008-5472.CAN-03-3505. View

14.

Jonuleit H, Tuting T, Stuge T, Paragnik L, Kandemir A, Lee P . A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001; 93(2):243-51. DOI: 10.1002/ijc.1323. View

15.

Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4(3):328-32. DOI: 10.1038/nm0398-328. View

16.

Mitchell M, Harel W, Groshen S . Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol. 1992; 10(7):1158-64. DOI: 10.1200/JCO.1992.10.7.1158. View

17.

Cranmer L, Trevor K, Hersh E . Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother. 2003; 53(4):275-306. PMC: 11032969. DOI: 10.1007/s00262-003-0432-5. View

18.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D . Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14631-8. PMC: 521999. DOI: 10.1073/pnas.0405743101. View

19.

Fields R, Shimizu K, Mule J . Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A. 1998; 95(16):9482-7. PMC: 21364. DOI: 10.1073/pnas.95.16.9482. View

20.

Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger J . Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998; 95(22):13141-6. PMC: 23738. DOI: 10.1073/pnas.95.22.13141. View